Navigation Links
Animal Protection Groups Condemn FDA's Endorsement of Animal Cloning
Date:1/15/2008

Animal Groups Say Greenlighting Production of Cloned Animals for Food is Irresponsible and Unethical; Research Finds Cloning Detrimental to Animals' Well-being

WASHINGTON, Jan. 15 /PRNewswire-USNewswire/ -- Farm Sanctuary, the nation's leading farm animal protection organization, in association with the American Anti-Vivisection Society (AAVS), the oldest organization in the nation dedicated to ending experiments on animals, denounce the Food and Drug Administration's (FDA) decision today to endorse the sale of cloned animals and their offspring for food. The agency moved forward with the announcement despite massive opposition from many corners, including Congress, the dairy industry, and animal protection and consumer advocacy groups. The FDA also called on producers to respect the U.S. Department of Agriculture's (USDA) request for a voluntary moratorium on the sale of cloned animals, though this moratorium would not apply to the progeny of cloned animals. Farm Sanctuary and AAVS are calling for a mandatory moratorium on cloned animals and their offspring to be established immediately.

The FDA's final risk assessment on animal cloning is filled with the same twists of logic, assumptions, and misrepresentations as the draft released in December 2006, despite thousands of comments criticizing the agency's analysis. For example, though the FDA acknowledges its responsibility to consider "the health of animals involved in the cloning process," the agency goes on to say that "our goal in evaluating the data on animal health... was not to determine whether the animals involved in the cloning process experienced adverse outcomes, but rather whether any of these outcomes are unique to cloning."

Simply tallying what problems cloned animals experience, without assessing the frequency or severity of those problems, hardly constitutes a rigorous science-based decision the FDA claims to have made. By the FDA's logic, something that causes sev
'/>"/>

SOURCE Farm Sanctuary
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
10. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
11. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6